Fenwick & West represented Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, in its underwritten public offering of 19,000,000 shares of its common stock at a price of $2.25 per share, with expected gross proceeds to Sierra Oncology of $42,750,000. As part of the offering, Sierra Oncology granted underwriters a 30-day option to purchase up to 2,850,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies LLC acted as the sole book-running manager for the offering. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.
The Fenwick transaction team included corporate partners Stephen Graham and Robert Freedman and associates Amanda Rose, Jane Jiang and Derrick Chapman.